Chardan Capital Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price

Krystal Biotech (NASDAQ:KRYS - Free Report) had its price objective hoisted by Chardan Capital from $212.00 to $218.00 in a research report report published on Thursday,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts have also recently issued reports on the stock. Citigroup increased their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. HC Wainwright reissued a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Krystal Biotech presently has an average rating of "Buy" and an average price target of $210.00.

Krystal Biotech Trading Up 2.9 %

KRYS stock traded up $5.24 during midday trading on Thursday, hitting $187.86. The stock had a trading volume of 293,600 shares, compared to its average volume of 260,850. The firm has a market cap of $5.40 billion, a P/E ratio of 62.83 and a beta of 0.84. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34. The business has a fifty day moving average price of $157.37 and a two-hundred day moving average price of $175.23.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the previous year, the business earned $0.30 earnings per share. Krystal Biotech's revenue for the quarter was up 116.4% on a year-over-year basis. On average, equities analysts anticipate that Krystal Biotech will post 6.14 EPS for the current year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company's stock, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 14.10% of the company's stock.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds have recently modified their holdings of the company. Summit Trail Advisors LLC purchased a new stake in shares of Krystal Biotech during the 3rd quarter worth approximately $1,893,000. Entropy Technologies LP purchased a new stake in shares of Krystal Biotech during the 4th quarter worth approximately $548,000. Swiss National Bank increased its stake in shares of Krystal Biotech by 8.0% during the 3rd quarter. Swiss National Bank now owns 39,100 shares of the company's stock worth $7,117,000 after purchasing an additional 2,900 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Krystal Biotech by 42.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock worth $8,239,000 after purchasing an additional 15,545 shares during the last quarter. Finally, Citigroup Inc. increased its stake in shares of Krystal Biotech by 65.4% during the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company's stock worth $6,386,000 after purchasing an additional 13,874 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).